Welcome to our dedicated page for MOLECULAR PARTNERS news (Ticker: MOLN), a resource for investors and traders seeking the latest updates and insights on MOLECULAR PARTNERS stock.
Molecular Partners AG (MOLN) is a clinical-stage biotechnology pioneer advancing DARPin therapeutics for oncology and radiopharmaceutical applications. This page provides investors and industry observers with official company announcements, clinical trial milestones, and strategic partnership updates.
Access the latest developments in MOLN's Radio-DARPin Therapy platform, Switch-DARPin candidates, and ophthalmology programs. Our curated news collection enables efficient tracking of regulatory filings, preclinical data disclosures, and financial results without promotional commentary.
Key content categories include clinical trial progress, collaborative research updates with partners like Orano Med, and technology platform innovations. All materials are sourced directly from company communications to ensure accuracy and compliance.
Bookmark this page for centralized access to Molecular Partners' verified announcements. For comprehensive analysis of MOLN stock performance, visit Stock Titan's dedicated market data section.
Molecular Partners announced that its antiviral drug, ensovibep, retains effectiveness against the newly identified Omicron variant of SARS-CoV-2, maintaining potency against key mutations. Ongoing testing on the full Omicron variant has commenced, with results expected soon. The company is conducting the global Phase 2-3 EMPATHY clinical study aimed at evaluating ensovibep's efficacy in treating early-stage COVID-19 patients. Topline phase 2 data is anticipated in early 2022, enhancing confidence in ensovibep as a viable treatment against emerging variants.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced participation by CEO Patrick Amstutz, Ph.D., in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021, at 8:00 AM EST. The presentation will be webcasted and available on the company’s website. Molecular Partners focuses on developing DARPin therapeutics for various diseases, including oncology and infectious diseases, partnering with leading pharmaceutical companies to enhance clinical and preclinical development.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced that the Data and Safety Monitoring Board (DSMB) has recommended halting the recruitment of patients for the ensovibep arm in the ACTIV-3 COVID-19 clinical study for hospitalized patients, as it did not meet required futility thresholds. While ensovibep remains well-tolerated, the study highlights challenges in demonstrating efficacy in late-stage COVID-19. Meanwhile, the ongoing EMPATHY study is assessing ensovibep's efficacy in non-hospitalized patients, with topline data anticipated in early 2022.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has initiated a Phase 1 clinical trial for MP0317, its second immuno-oncology DARPin candidate. This therapy aims to deliver tumor-localized immune activation while minimizing systemic toxicity, a common issue with existing CD40-targeting agents. Preclinical results indicate MP0317 can activate immune cells effectively within tumors. The open-label study will enroll up to 30 patients across six cohorts in Europe, assessing safety, tolerability, and pharmacodynamics. The innovative DARPin technology may enhance the efficacy of cancer immunotherapies while protecting healthy tissue.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced its interim management statement for Q3 2021, highlighting advancements in its COVID-19 program. The company has enrolled over 700 patients in two global studies and is preparing for significant data assessments. Financially, as of September 30, 2021, it reported CHF 154.3 million in cash, with an operating loss of CHF 47.6 million. The company expects total expenses for 2021 to be between CHF 70-75 million. Topline data from ongoing trials are expected in early 2022, marking critical milestones for the company's therapeutic candidates.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced the presentation of in vitro data for their COVID-19 therapeutic, ensovibep, at the ISIRV and WHO conference. The data confirms ensovibep's ability to inhibit all known SARS-CoV-2 variants of concern, including the Delta variant. The company will also present a Trial in Progress poster on the EMPATHY clinical trial, which evaluates ensovibep's efficacy in COVID-19 patients. Ensovibep is currently in late-stage trials, highlighting its potential in addressing unmet treatment needs amidst evolving variants.
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a biotech firm specializing in DARPin® therapeutics, announced that CEO Patrick Amstutz will present at two virtual healthcare investor events in September 2021. The first event is the Morgan Stanley 19th Annual Global Healthcare Conference on September 10 at 11:00 AM ET. The second is the H.C. Wainwright 23rd Annual Global Investment Conference, happening from September 13-15, with presentations available on demand from September 13 at 7:00 AM ET. Webcasted presentations will be accessible on the company's website.
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) announced significant advancements in its COVID-19 therapeutic trials, particularly its lead candidate ensovibep. Two late-stage trials, EMPATHY and ACTIV-3, have been initiated with positive interim data expected in the second half of 2021. The FDA awarded Fast Track designation for ensovibep, which maintains efficacy against SARS-CoV-2 variants. Financial results for H1 2021 showed revenues of CHF 4.4 million, but the firm reported an operating loss of CHF 34.8 million, reflecting rising expenses and ongoing cash utilization. Cash reserves stand at CHF 174.3 million, supporting operations until H2 2023.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced the return of global rights to its investigational drug abicipar pegol from AbbVie due to the termination of their collaboration agreement. This drug targets neovascular age-related macular degeneration (nAMD) and Diabetic Macular Edema (DME). Molecular Partners has made improvements in the drug's manufacturing and formulation to potentially reduce inflammatory side effects. The company plans to evaluate next steps for abicipar while continuing its discovery alliance with AbbVie for other ophthalmic therapies.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) reports progress on its antiviral candidate, ensovibep, designed to combat SARS-CoV-2. It retains full potency against all known variants, including Delta. The EMPATHY Phase 2/3 trial is enrolling patients across 5 countries, with expansion planned. The ACTIV-3 trial for hospitalized patients is actively recruiting. A subcutaneous formulation is set for clinical trials in H2 2021. Ensovibep shows potential for differentiated treatment amid mixed vaccination rates globally.
